Point of Care Diagnostic Market Overview

 

Point of care Diagnostic is testing that is performed near or at the site of a patient with the result leading to possible change in the care of the patient, which facilitates better disease diagnosis, monitoring, and management. It enables quick medical decisions to diagnose diseases at a very early stage, leading to improved health outcomes for patients by enabling the early start of treatment.

 

Point of Care Diagnostic Market experiencing significant growth of XX% every year and is expected to continue its growth during the forecast period. F. Hoffmann-La Roche Ltd., Abbott, Danaher, BD, and Qiagen are well-established players in the Point of Care Diagnostic Market. F. Hoffmann-La Roche Ltd. is a global leader in the Point of Care Diagnostic Market which offers a broad portfolio of POC tests across various categories. This includes leading positions in blood glucose monitoring systems (Accu-Chek brand), rapid influenza tests (Sofia Influenza A+B FIA), and tests for other infectious diseases, cholesterol, and cardiac health. North America region held the dominant segment in the Point of Care Diagnostic Market in 2023. The Point of Care Diagnostic Market is mainly driven by the rising prevalence of infectious diseases worldwide and the Shift toward healthcare decentralization in this region. which leads to the rapid growth of the Point of Care Diagnostic Market globally in the forecasting year 2024-2030. Accuracy and Reliability are the main challenges in the Point of Care Diagnostic Market. Based on Product, Blood Glucose Monitoring dominates the point of care diagnostic market amongst all the product types and currently holds the largest market share of XX% in 2023, this is due to the increasing focus on diabetes management and the development of user-friendly continuous glucose monitoring.

 

 

To get more Insights: Request Free Sample Report

 

Point of Care Diagnostic Market Dynamics

Point of Care Diagnostic Market Drivers

 

The rising prevalence of infectious diseases worldwide

 

POC tests allow for rapid identification of infectious diseases at the Point of Care Diagnostic, which benefits patients by enabling faster treatment, while public health officials benefit from improved disease surveillance. This comprehensive approach to managing outbreaks enhances individual health outcomes and fosters public health management in areas with high infection rates or restricted access to conventional healthcare facilities., Point of Care Diagnostic is continuously evolving due to the focus on novel infectious risks, which assures quicker response times and better availability for outbreaks in the future. UNITAID, a global health organization announced a USD 30 million investment to accelerate the introduction of advanced diagnostic tools for infectious diseases, to improve access to same-day test results to enable more people to quickly access appropriate treatment. According to the National Center for Biotechnology Information, India has around 2.8 million new tuberculosis cases each year, The market demand for these testing devices is expected to increase due to the growing number of patients with chronic illnesses and the growing awareness of early screening and diagnosis drives the Point of Care Diagnostic Market.

 

• According to WHO Global Tuberculosis Report 2023, in 2022 Tuberculosis ranked as the second leading cause of death globally among single infectious agents following COVID-19. Globally, the newly diagnosed tuberculosis cases reached 7.5 million in 2022.

 

• According to UNAIDS, approximately 39 million people were suffering from HIV-AIDS globally as of 2022, and an estimated 1.3 million individuals acquired HIV.

 

• According to the World Health Organization report, the confirmed COVID-19 deaths worldwide are 7,053,524 as of July 2024.

 

Shift toward healthcare decentralization

 

The shift towards healthcare decentralization is fueled by the point of care diagnostic Market, which has several benefits, including less dependence on traditional lab testing infrastructure, quicker diagnosis and treatment initiation leading to better patient outcomes, enhanced accessibility for patients living in remote areas or with limited mobility, and possibly lower healthcare costs. Technological developments resulted in the development of POC equipment that is lightweight, easy to use, and able to perform a wide variety of tests. This makes it simple to use in a variety of healthcare settings, such as pharmacies, clinics, and patient homes. It also makes it easier to integrate with telehealth platforms to provide remote consultations and better care coordination. A study published in "Health Affairs" analyzes the cost-effectiveness of decentralized care models for chronic disease management. It finds that for certain conditions, decentralized care lead to improved outcomes and lower costs.

 

• According to the National Center for Biotechnology Information, the Estimated average expected total treatment cost was USD 3390.56 for the hospital-based model and USD 1724.1 for the decentralized model for a patient treated for MDR-TB in India, generating potential savings of USD 1666.50 per case, with ICER USD 2382.68 per QALY gained.

 

• McKinsey & Company explores the potential of decentralized care models to improve healthcare access, affordability, and patient experience. It highlights the role of technology, including POC diagnostics, in enabling this shift. According to McKinsey & Company up to USD 265 billion worth of care services (representing up to 25 percent of the total cost of care) for Medicare fee for service and Medicare Advantage beneficiaries could shift from traditional facilities to the home by 2025 without a reduction in quality or access.

 

Point of Care Diagnostic Market Challenges

 

Accuracy and Reliability

 

Accuracy and Reliability are the main challenges in POC tests, several factors affect the accuracy of POC tests, including the limited sample size used in the tests compared to lab settings, the possible impact of environmental factors (temperature, humidity), mild differences in performance between different POC devices for the same test, and the possibility of errors due to inadequate user training or a lack of experience in sample collection, test execution, or result interpretation are the main challenge for Point of Care Diagnostic Market. Whereas the sensitivity and specificity of POC testing are increasing due to developments in microfluidics and biosensor design. While manufacturers are creating more reliable internal controls for their gadgets, regulatory authorities are striving to set more stringent performance standards. Accurate test administration and interpretation are further ensured by placing a strong emphasis on appropriate user training and continuing education for healthcare professionals. POC test for strep throat has a sensitivity of 90% which means it correctly identifies 90% of true strep throat cases and a specificity of 95% which means it correctly identifies 95% of cases that are not strep throat. Regulatory bodies such as the US Food and Drug Administration review the accuracy and reliability of data submitted by manufacturers for POC device approval.

 

• Dexcom a U.S.-based company is exploring AI-powered Calibration Algorithms and the potential of artificial intelligence (AI) for even more sophisticated sensor data analysis and real-time calibration adjustments in their CGM devices.

 

• Abbott Laboratories,  an American multinational health care and medical devices company’s i-STAT analyzers, used for various POC tests, offer cloud connectivity for data management, allowing healthcare providers to access patient results remotely and monitor instrument health with built-in calibration and self-correction mechanisms to minimize errors and improve test consistency.

 

Point of Care Diagnostic Market Segment Analysis

 

Based on Product, Blood Glucose Monitoring dominates the point of care diagnostic market amongst all the product types and currently holds the largest market share of XX% in 2023, this is due to the increasing focus on diabetes management and the development of user-friendly continuous glucose monitoring (CGM) systems are driving growth. According to the International Diabetes Federation, 537 million adults (20-79 years) living with diabetes in 2022, and the diabetes population is expected to increase to 643 million by 2030 and reach 783 million by 2045, treating them costs around 12% of all healthcare spending globally, according to the World Health Organization. Managing diabetes is essential to avoiding complications such as renal failure, heart disease, stroke, and blindness. Patients with diabetes regularly check their blood sugar levels throughout the day by using POC blood glucose meters. Continuous glucose monitoring (CGM) systems are transforming the treatment of diabetes. Compared to conventional finger sticks, these small devices provide a more complete view of glucose changes by providing real-time blood sugar data. According to a report, 129 million people in China currently have diabetes, whereas 82 million people are anticipated to have the disease in India by 2027

 

• By 2045, IDF projections show that 1 in 8 adults, approximately 783 million, will be living with diabetes, an increase of 46%. 

 

• In March 2024, the FDA approved the first Over the Counter Continuous Glucose Monitor (CGM), the Dexcom G7. This device allows people with diabetes to track their glucose levels without a prescription.

 

Point of Care Diagnostic Market Regional Insights

 

North America dominated the market and accounted for a XX% share in 2023. rapid adoption of advanced point of care testing products, and the presence of key players in the region like Abbott, Danaher, BIOMERIEUX, BD, Siemens Healthineers AG, and Dexcom have contributed to Point of Care Diagnostic market expansion. Supportive government-sponsored research bodies such as the American Heart Association, International Diabetes Federation, and American Diabetes Association, along with dedicated academic institutions, have fostered advancements in PoC diagnostics. High healthcare costs encourage the adoption of innovative technology and investment in them. Advanced healthcare infrastructure and favorable reimbursement policies create an environment that is favorable to the integration and utilization of POC devices and the growing aging population with chronic illnesses conditions requires convenient testing options and generally high awareness of POC diagnostics which drives the Point of Care Diagnostic Market. Alzheimer's is the 5^th leading cause of death among Americans age 65 and older in 2023, an estimated 6.9 million Americans age 65 and older are living with Alzheimer's today with 119,399 deaths in 2021. Fujirebio a global leader in neurology diagnostics, Fujirebio offers established Alzheimer's Disease diagnostic tools. They are developing POC tests for earlier Alzheimer's detection or targeting other neurodegenerative diseases.

 

• FUJIFILM SonoSite introduced Point-of-Care ultrasound systems for physicians nationwide, catering to the growing demand for portable and user-friendly diagnostic devices which enhances patient care by reducing the need for transfers to radiology departments.

 

The Asia Pacific region is expected to witness the highest growth rate in the PoC diagnostics industry driven by the increasing prevalence of chronic diseases in this region and a large patient pool. Because of their increasing healthcare infrastructures, China and India are going to be important markets in this region. The Indian government has shown support for promoting POC diagnostics for various applications like HIV testing and diabetes management. According to a report, in India, over 4 million health workers are needed in the nation, but 70% of Indians live in rural areas, while over 60% of the current workforce is employed in metropolitan areas. The National AIDS Control Organization (NACO) has established national guidelines for HIV testing, including recommendations for using POC tests.

 

• In June 2023, Sysmex Corporation announced the launch of an assay kit in Japan to identify amyloid beta accumulation in the brain, a cause of Alzheimer’s disease.

 

Point of Care Diagnostic Market Scope

 

Point of Care Diagnostic Market Scope
Market Size in 2023	USD 42.53 billion
Market Size in 2030	USD 64.80 billion
CAGR (2024-2030)	6.2%.
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Segment Analysis	by Product Blood Glucose Monitoring Infectious Disease Testing Cardiometabolic Disease Testing Pregnancy & Fertility Testing Haematology Testing Others
	by Sample Blood Nasal and Oropharyngeal Swabs Urine Others
	by Mode of Purchase Prescription-based Products OTC Products
	by Platform Lateral Flow Assays Dipsticks Microfluidics Molecular Diagnostics Polymerase Chain Reaction (PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) Other Molecular Diagnostic Technologies Immunoassays
	by End User Clinics Hospitals Home Assisted Living Healthcare Facilities Laboratory

 

Point of Care Diagnostic Market by Region

 

North America (United States, Canada, and Mexico)

Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)

Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)

South America (Brazil, Argentina, Rest of South America)

 

Point of Care Diagnostic Market Key Players

 

1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Danaher (USA)
3. BD (USA)
4. Qiagen (Germany)
5. Abbott (USA)
6. Siemens Healthcare AG (Germany)
7. bioMerieux SA (France)
8. Zoetis, Inc. (USA)
9. Instrumentation Laboratory (USA)
10. Nova Biomedical (USA)
11. Quidel Corp.(USA)
12. Trividia Health, Inc.(USA)
13. Sekisui Diagnostics (Japan)